PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms December 2, 2025 9:30 AM EST
Company Participants
Matthew Klein – CEO & Director
Christopher Trotta – Vice President of Biology
Anu Bhattacharyya
Conference Call Participants
Brian Abrahams – RBC Capital Markets, Research Division
Lut Ming Cheng – JPMorgan Chase & Co, Research Division
Tazeen Ahmad – BofA Securities, Research Division
Joseph Thome – TD Cowen, Research Division
Yuxi Dong – Jefferies LLC, Research Division
Huidong Wang – Barclays Bank PLC, Research Division
Kyuwon Choi – Goldman Sachs Group, Inc., Research Division
Jeff Trimmer
Mayzie Johnston
Benjamin Burnett – Wells Fargo Securities, LLC, Research Division
Kristen Kluska – Cantor Fitzgerald & Co., Research Division
Judah Frommer – Morgan Stanley, Research Division
Conversation
Matthew Klein
CEO & Director
Okay. Good morning, everyone. Thank you for joining us at PTC’s R&D Day. Thank you for those who are joining us live here in New York at the Yale Club as well as those who are joining us virtually online. I’m joined today by our Chief Scientific Officer, Neil Almstead; our Chief Medical Officer, Lee Golden; members of our R&D leadership team who will be presenting today as well as members of our IR team.
For the past 2 years, a lot of the focus on PTC has been on our late-stage programs and commercial products, which makes a lot of sense. However, over that time, we brought the same emphasis on focus, and execution to our earlier-stage R&D programs. When we did a restructuring a couple of years ago, we made the decision that we were going to focus on small molecule therapies as well as focus on science that PTC can uniquely leverage to deliver transformative therapies for patients with diseases of high unmet need.
Specifically, this meant we were going to focus on our small molecule splicing platform as well
